Polaris Partners

Today, we announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class clinical-stage in vivo CAR-T therapy, being developed for the treatment of autoimmune diseases. AbbVie’s position as a world-leader in immunology moves us closer to delivering on our mission to multiply the possibilities and transform patient care globally. We are grateful for the contributions of our team, our scientific founders, and our investors, that have positioned Capstan as the leader in in vivo CAR-T. Learn more in today’s announcement: https://lnkd.in/eSJ4geqq

Cohere Health, the leader in clinical intelligence solutions for health plans and risk-bearing providers, today announced it has raised $90 million in Series C funding. Led by Temasek, with continued support from Deerfield Management, Define Ventures, Flare Capital Partners, Longitude Capital, and Polaris Partners, this new investment brings Cohere’s total funding to $200 million. The new investment will accelerate Cohere’s next phase of growth–scaling the Cohere Unify™ platform, expanding into new clinical use cases, and deepening investment in our AI-powered product portfolio. Cohere Unify enables critical collaboration points between health plans and providers, and modernizes UM by personalizing provider workflows and optimizing engagement through real-time performance data. Together, these capabilities lay the foundation for our broader vision of transforming clinical decision-making. ▶️ Read more about how this investment accelerates Cohere's reach into broader clinical workflows and reinforces our market leadership in prior authorization transformation: https://lnkd.in/enHmwZ98

Egnyte is proud to announce strategic growth investments from GI Partners and TA Associates that will help accelerate the company’s global growth in years to come. This represents a significant milestone in Egnyte’s journey and the opportunity to unlock more research and development opportunities for the company’s growth and expansion into new verticals and global markets. Read the full press release: bit.ly/4gYP540

We're excited to share that we've received Fast Track Designation in AML! https://lnkd.in/e-JYPBdP

We’re excited to announce that Roche has exercised its option to license one of our next-generation AI-designed AAV vectors for neurological diseases! 🧬🚀 More on this key milestone for AI in gene therapy: https://lnkd.in/eYKxccMq

Today we have announced $70M in new funding to advance our Mucosal Protection Platform. Our non-vaccine approach utilizes broadly protective intranasally administered antibodies to free people from the threat of respiratory viruses, such as influenza and coronaviruses. The funding round was supported by co-leads ClavystBio (a life sciences venture investor established by Temasek) and Polaris Partners, with participation by Qiming Venture Partners and existing investors including GV (Google Ventures) and Casdin Capital, LLC, who led previous funding rounds. Read more... https://lnkd.in/gn8ye6dv

🚀 Big news from FIRE1! 🚀 We’re thrilled to announce that FIRE1 has secured $120 million in financing to accelerate our mission of transforming heart failure care! This funding, led by Polaris Partners and Elevage Medical Technologies, alongside new investors Longitude Capital, Sands Capital and existing investors, will enable us to complete a pivotal clinical trial for our Norm™ heart failure management solution and brings us one step closer to completing our mission to give millions of people around the world with heart failure their normal back! Heart failure affects millions, yet traditional management remains reactive and hospital-centric. Norm™ empowers patients with physician-directed self-management, to reduce hospitalizations and ease the burden on healthcare systems. Breakthrough Device Designation We're also honored to receive Breakthrough Device Designation from the FDA and acceptance into the Total Product Lifecycle Advisory Program (TAP) based on our innovative approach in tackling one of healthcare’s greatest challenges. A warm welcome to Ellie McGuire (Polaris Partners) and Michael Wasserman (Elevage Medical Technologies) to our Board of Directors! This is more than just funding—it’s a step toward revolutionizing heart failure care and empowering patients worldwide. Stay tuned as we continue this exciting journey! 🔗 Learn more: www.fire1foundry.com Andera Partners New Enterprise Associates (NEA) Novo Holdings Lightstone Ventures Gilde Healthcare Gimv National Treasury Management Agency Seventure Partners Medtronic Maxwell Bikoff Jake Merrill #FIRE1 #HeartFailure #Patientempowerment #NormHF #YourNormalBack

Today we celebrate our new partnership with Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of advancing a small molecule condensate modulator (#cmod) that corrects an underlying pathology shared by ~97 % of all ALS patients: the mislocalization of the TDP-43 splicing factor into aberrant cytoplasmic condensates. Our expertise in #condensate science will complement MTPC’s unrivaled expertise in ALS drug development to progress a c-mod discovered in house using our proprietary platform. 🔬 The c-mod selectively restores nuclear localization of TDP-43, promotes neuronal health in in vitro pre-clinical models, and demonstrated improvement of multiple ALS biomarkers in in vitro and in vivo preclinical models.  Read more about the science and financial details of this exciting new milestone here: https://lnkd.in/ghWguxv5  

🧠 🚀 NEWS: Today marks a pivotal moment in Muna’s evolution as we announce a strategic alliance with GSK. This multi-year research effort leverages our all-in-human MiND-MAP spatial multi-omics approach to identify and validate new drug targets and treatment pathways for Alzheimer’s disease. Muna will receive an upfront payment of €33.5 million, with eligibility to receive up to €140 million per target in milestone payments. Read the release here: https://lnkd.in/erByz862 #alzheimers #neurodegeneration #CNS #GSK #biotech